Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis
While the correlation between treatment effects on PFS and OS was weak in ESCC, it was moderate in PD-L1-low GEA, and good in PD-L1-high GEA. Therefore, PFS is an adequate co-primary endpoint in future trials investigating novel ICIs-based regimens in GEA, especially if the analyses are pre-planned in PD-L1-high subgroups.
Authors
- Sylvie Lorenzen
- Alberto Giovanni Leone (ORCID: https://orcid.org/0000-0001-9365-2160)
- Yelena Y. Janjigian (ORCID: https://orcid.org/0000-0002-5357-5858)
- María Alsina (ORCID: https://orcid.org/0000-0003-4835-7159)
- Radka Obermannová (ORCID: https://orcid.org/0000-0001-7363-7879)
- Florian Lordick (ORCID: https://orcid.org/0000-0001-8591-9339)
- Raghav Sundar (ORCID: https://orcid.org/0000-0001-9423-1368)
- Michael Masetti (ORCID: https://orcid.org/0000-0002-9639-3472)
- Samuel Jacob Klempner (ORCID: https://orcid.org/0000-0002-4062-0808)
- Filippo Pietrantonio (ORCID: https://orcid.org/0000-0002-8530-8420)
- Elizabeth Smyth (ORCID: https://orcid.org/0000-0002-4667-1817)
- Fausto Petrelli
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Masaryk University (CZ)
- Oxford Health NHS Foundation Trust (GB)
- Yale University (US)
- Massachusetts General Hospital (US)
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie (DE)
- Masaryk Memorial Cancer Institute (CZ)
- Navarrabiomed (ES)
- University Hospital Leipzig (DE)
- Oxford University Hospitals NHS Trust (GB)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Azienda Ospedaliera Treviglio (IT)
- Leipzig University (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1016/j.ejca.2025.116155
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro